- Home
- CRGX vs IPHA Comparison
CRGX vs IPHA Comparison
Compare CRGX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- IPHA
- Stock Information
- Founded
- CRGX 2021
- IPHA 1999
- Country
- CRGX United States
- IPHA France
- Employees
- CRGX N/A
- IPHA N/A
- Industry
- CRGX
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CRGX
- IPHA Health Care
- Exchange
- CRGX Nasdaq
- IPHA Nasdaq
- Market Cap
- CRGX 180.4M
- IPHA 160.1M
- IPO Year
- CRGX 2023
- IPHA 2019
- Fundamental
- Price
- CRGX $4.64
- IPHA $1.97
- Analyst Decision
- CRGX Hold
- IPHA Strong Buy
- Analyst Count
- CRGX 7
- IPHA 1
- Target Price
- CRGX $4.67
- IPHA $11.50
- AVG Volume (30 Days)
- CRGX 653.7K
- IPHA 28.5K
- Earning Date
- CRGX 05-13-2025
- IPHA 03-27-2025
- Dividend Yield
- CRGX N/A
- IPHA N/A
- EPS Growth
- CRGX N/A
- IPHA N/A
- EPS
- CRGX N/A
- IPHA N/A
- Revenue
- CRGX N/A
- IPHA $20,831,349.00
- Revenue This Year
- CRGX $58.18
- IPHA $220.44
- Revenue Next Year
- CRGX N/A
- IPHA $81.85
- P/E Ratio
- CRGX N/A
- IPHA N/A
- Revenue Growth
- CRGX N/A
- IPHA N/A
- 52 Week Low
- CRGX $3.00
- IPHA $1.29
- 52 Week High
- CRGX $25.45
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CRGX 59.08
- IPHA 53.30
- Support Level
- CRGX $3.58
- IPHA $1.81
- Resistance Level
- CRGX $4.17
- IPHA $2.00
- Average True Range (ATR)
- CRGX 0.26
- IPHA 0.14
- MACD
- CRGX 0.12
- IPHA 0.02
- Stochastic Oscillator
- CRGX 92.98
- IPHA 53.76
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.